Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Free Cash Flow (2022 - 2025)

Stoke Therapeutics has reported Free Cash Flow over the past 4 years, most recently at -$31.0 million for Q4 2025.

  • For Q4 2025, Free Cash Flow fell 33.51% year-over-year to -$31.0 million; the TTM value through Dec 2025 reached $44.9 million, up 151.68%, while the annual FY2025 figure was $44.9 million, 151.68% up from the prior year.
  • Free Cash Flow for Q4 2025 was -$31.0 million at Stoke Therapeutics, down from -$30.4 million in the prior quarter.
  • Over five years, Free Cash Flow peaked at $131.8 million in Q1 2025 and troughed at -$31.0 million in Q4 2025.
  • A 4-year average of -$10.0 million and a median of -$22.1 million in 2023 define the central range for Free Cash Flow.
  • Biggest five-year swings in Free Cash Flow: plummeted 166.86% in 2023 and later surged 636.25% in 2025.
  • Year by year, Free Cash Flow stood at -$22.8 million in 2022, then rose by 8.36% to -$20.9 million in 2023, then fell by 11.33% to -$23.2 million in 2024, then tumbled by 33.51% to -$31.0 million in 2025.
  • Business Quant data shows Free Cash Flow for STOK at -$31.0 million in Q4 2025, -$30.4 million in Q3 2025, and -$25.4 million in Q2 2025.